![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A 12-week Interferon-free Treatment Regimen With ABT-450/r, ABT 267, ABT-333, and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-naïve Patients and 93% in Prior Null Responders With HCV Genotype 1 Infection
|
|
|
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
Kris V Kowdley1, Eric Lawitz2, Fred Poordad3, Daniel E Cohen4, David Nelson5,
Stefan Zeuzem6, Gregory T Everson7, Paul Kwo8, Graham R Foster9, Mark Sulkowski10,
Wangang Xie4, Tami Pilot-Matias4, George Liossis4, Lois Larsen4, Amit Khatri4,
Thomas Podsadecki4, Barry Bernstein4
1Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States; 2Alamo Medical Research,
San Antonio, Texas, United States; 3University of Texas Health Science Center, San Antonio, Texas, United States; 4Abbott Laboratories, Abbott Park, Illinois, United States; 5University of Florida College of Medicine, Gainesville, Florida, United States; 6J.W. Goethe University, Frankfurt, Germany; 7University of Colorado Denver, Aurora, Colorado, United States; 8Indiana University, Indianapolis, Indiana, United States; 9Queen Marys University of London, Barts Health, London, United Kingdom; 10Johns Hopkins University, Baltimore, Maryland, United States
![AASLD1.gif](../images/111312/111312-9/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-9/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-9/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-9/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-9/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-9/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-9/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-9/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-9/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-9/AASLD10.gif)
![AASLD11.gif](../images/111312/111312-9/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|